l) Any major surgery within 4 weeks of the first dose of study treatment. Participants must have recovered from the effects of a major surgery or significant traumatic injury at least 14 days before the first dose of study treatment. i) Participants who have received a live / attenuated vaccine within 30 days of first treatment. (1).The use of inactivated seasonal influenza vaccines (eg, Fluzone®) will be permitted on study without restriction. m) Receipt of packed red blood cells or platelet transfusion within 2 weeks of the first dose of study treatment. n) Any known or underlying medical or psych iatric condition and/or social reason that, in the opinion of the investigator or Sponsor, could make the administration of study treatment hazardous to the participants or could adversely affect the ab ility of the participant to comply with or tolerate the study. o) WOCBP who are pregnant or breastfeeding. 4) Allergies and Adverse Drug Reaction a) History of allergy to study treatment components. b) History of severe hypersensitivity reaction to any mAb. 5) Other Exclusion Criteria a) Prisoners or participants who are involuntarily incarcerated. (Note: under certain specific circumstances, and only in countries where local regulations permit, a person who has been imprisoned may be included or permitted to continue as a participant. Strict conditions apply, and BMS approval is required.) b) Participants who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness. c) Participants with serious or uncontrolled medical disorders Eligibility criteria for this study have been carefully considered to ensure the safety of the study participants and that the results of the study can be used.